Invitation to live investor meeting with Chordate Medical 29 December at 14:00

On Thursday 29 December at 14:00, Chordate's CEO Anders Weilandt will present the Company, the rationale for the Rights Issue and further information on the Company's strategy and future plans. The presentation will be held in Swedish and will be broadcast live, hosted by Västra Hamnen Corporate Finance.

After the presentation, participants will have the opportunity to ask questions. The number of seats is limited, and the Company therefore recommends registering in advance to be assured of a seat. Registration for the investor meeting can be done via the link below.

Time: Thursday 29 December, 14:00 (2 p.m.)


A recording of the broadcast will be available afterwards on Chordate's website and on the Västra Hamnen Corporate Finance YouTube-kanal.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact